Didier Bouscary

Didier Bouscary

Auto-generated profile, based on publicly available information

Didier Bouscary

Universite Paris Cite, INSERM, CNRS, Institut Cochin, Paris - France ; Hematology care unit and laboratory, AP-HP, Hopital Cochin, Paris - France

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2016 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
AKAsim Khwaja
Asim Khwaja
MBMagnus Bjorkholm
Magnus Bjorkholm
RGRosemary E. Gale
Rosemary E. Gale
RLRoss L. Levine
Ross L. Levine
CJCraig T. Jordan
Craig T. Jordan
DLDavid C. Linch
David C. Linch

15 January 2001 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YZYael Zermati
Yael Zermati
GCGarrido Carmen
Garrido Carmen
SASophie Amsellem
Sophie Amsellem
SFSerge Fishelson
Serge Fishelson
DBDidier Bouscary
Didier Bouscary
OHOlivier Hermine
Olivier Hermine
The cysteine proteases known as caspases play a central role in most apoptotic pathways. Here, we show that caspase inhibitors arrest the maturation of human erythroid progenitors at early stages of differentiation, before nucleus and chromatin condensation. Effector caspases such as caspase-3 are transiently activated through the mitochondrial pathway during erythroblast differentiation and cleave proteins involved in nucleus integrity (lamin B) and chromatin condensation (acinus) without inducing cell death and cleavage of GATA-1. These observations indicate a new function for caspases as key proteases in the process of erythroid differentiation.

10 September 2015 in Blood
Verified
Journal Article
Closed access
PDF file
NJNathalie Jacque
Nathalie Jacque
ARAnne Marie Ronchetti
Anne Marie Ronchetti
CLClément Larrue
Clément Larrue
GMGodelieve Meunier
Godelieve Meunier
RBRudy Birsen
Rudy Birsen
DBDidier Bouscary
Didier Bouscary
Cancer cells require glutamine to adapt to increased biosynthetic activity. The limiting step in intracellular glutamine catabolism involves its conversion to glutamate by glutaminase (GA). Different GA isoforms are encoded by the genes GLS1 and GLS2 in humans. Herein, we show that glutamine levels control mitochondrial oxidative phosphorylation (OXPHOS) in AML cells. Glutaminase C (GAC) is the GA isoform that is most abundantly expressed in AML. Both knockdown of GLS1 expression and pharmacological GLS1 inhibition by the drug CB-839 can reduce OXPHOS, leading to leukemic cell proliferation arrest and apoptosis without causing cytotoxic activity against normal human CD34+ progenitors. Strikingly, a GLS1-knockdown dramatically inhibited AML development in NSG mice. The anti-leukemic activity of CB-839 was abrogated by both the expression of a hyperactive GACK320A allele and the addition of the TCA cycle product α-ketoglutarate, indicating the critical function of GLS1 in AML cell survival. Finally, glutaminolysis inhibition activated mitochondrial apoptosis and synergistically sensitized leukemic cells to priming with the BCL-2 inhibitor ABT-199. These findings show that targeting glutamine addiction via GLS1 inhibition offers a potential novel therapeutic strategy for AML.

30 November 2009 in Haematologica
Verified
Journal Article
Closed access
SPS. Park
S. Park
Nicolas ChapuisNicolas Chapuis
Nicolas Chapuis
JTJerome Tamburini-Bonnefoy
Jerome Tamburini-Bonnefoy
BVBardet Valerie
Bardet Valerie
PCP. Cornillet-Lefebvre
P. Cornillet-Lefebvre
DBD. Bouscary
D. Bouscary
The PI3K/AKT and mTOR signaling pathways are activated in acute myeloid leukemia, including in the more immature leukemic populations. Constitutive PI3K activation is detectable in 50% of acute myeloid leukemia samples whereas mTORC1 is activated in all cases of this disease. In leukemic cells, the PI3K activity relates to the expression of the p110delta isoform of class IA PI3K. Constitutive PI3K activation is the result of autocrine IGF-1/IGF-1R signaling in 70% of acute myeloid leukemia samples but specific inhibition of this pathway does not induce apoptosis. Specific inhibition of PI3K/AKT or mTORC1 alone in vitro has anti-leukemic effects which are essentially exerted via the suppression of proliferation. However, as mTORC1 activation is independent of PI3K/AKT in acute myeloid leukemia, dual PI3K and mTOR inhibitors may induce apoptosis in blast cells. Moreover, mTORC1 inhibition using sirolimus overactivates PI3K/AKT via the upregulation of IRS2 expression and by favoring IGF-1/IGF-1R autocrine signaling. Recent data also indicate that mTORC1 does not control protein translation in acute myeloid leukemia. These results open the way for the design of direct inhibitors of protein synthesis as novel acute myeloid leukemia therapies and also for the development of second generation mTOR inhibitors (the TORKinhibs).

14 November 2013 in Blood
Verified
Journal Article
Open access
PDF file
LWLise Willems
Lise Willems
NJNathalie Jacque
Nathalie Jacque
Arnaud JacquelArnaud Jacquel
Arnaud Jacquel
NNNathalie Neveux
Nathalie Neveux
TMThiago Trovati Maciel
Thiago Trovati Maciel
DBDidier Bouscary
Didier Bouscary
Key Points: Glutamine removal and knockdown of the glutamine transporter SLC1A5 have antileukemic activity in AML. The glutaminase activity of l-asparaginase inhibits mTORC1 and protein synthesis and induces a strong autophagy in AML.

23 September 2002 in Oncogene
Verified
Journal Article
Closed access
FPFrédéric Pène
Frédéric Pène
YCYann-Erick Claessens
Yann-Erick Claessens
OMOdile Muller
Odile Muller
FVFranck Viguié
Franck Viguié
PMPatrick Mayeux
Patrick Mayeux
DBDidier Bouscary
Didier Bouscary